© Reuters. FILE PHOTO: An Amgen signal is seen on the firm’s workplace in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith
(Reuters) – The US Federal Commerce Fee (FTC) is anticipated to file a lawsuit as early as Tuesday to dam Amgen Inc (NASDAQ:)’s $27.8 billion deal to purchase Horizon Therapeutics (NASDAQ:) PLC, an individual aware of the matter instructed Reuters.
Final yr, Amgen agreed to purchase Horizon to strengthen its uncommon ailments medication portfolio and mentioned it hopes to finish the deal within the first half of 2023.
Amgen mentioned on Monday it wasn’t conscious of any determination made by the company.
US Senator Elizabeth Warren, an outspoken critic of company consolidation, wrote to the company earlier this yr expressing her considerations on pharmaceutical offers together with the Amgen deal, citing menace to competitors within the sector.
The deal would give Amgen two fast-growing medication, the thyroid eye illness remedy Tepezza and gout remedy Krystexxa. Amgen hopes they’ll act as a bulwark towards competitors for its blockbuster arthritis drug Enbrel.
